Primary Sjögren’s Syndrome Accompanied by Clinical Features of TAFRO Syndrome

Joint Authors

Migita, Kiyoshi
Suzuki, Eiji
Ichimura, Takuya
Kimura, Satoru
Kanno, Takashi

Source

Case Reports in Rheumatology

Issue

Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-7, 7 p.

Publisher

Hindawi Publishing Corporation

Publication Date

2020-09-17

Country of Publication

Egypt

No. of Pages

7

Main Subjects

Diseases

Abstract EN

Sjögren’s syndrome (SS) is associated with not only sicca symptoms but also various symptoms caused by extraglandular manifestation.

The pathophysiology and comorbidities of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly), which is thought to be a variant of multicentric Castleman’s disease, are not fully understood, and there are few data on the effectiveness of treatments.

We report a patient of SS with TAFRO syndrome-like clinical features.

A 52-year-old woman was admitted to our hospital because of abdominal distension.

Laboratory data showed thrombocytopenia, and image findings showed massive ascites without evidence of malignant disease as confirmed by cytology.

She was diagnosed with SS based on dysfunction of salivary secretion and positivity for anti-Ro/SS-A and La/SS-B antibodies, accompanied by clinical features of TAFRO syndrome based on the presence of anasarca and thrombocytopenia.

High-dose corticosteroid for inflammation, anasarca, and thrombocytopenia was not effective.

Cyclosporine was administered next, but anasarca and thrombocytopenia did not immediately improve until tolvaptan and eltrombopag were added.

Although tolvaptan and eltrombopag were used for only a few months, the patient maintained a good condition with cyclosporine and low-dose prednisolone.

In SS patients, activation of antigen-specific T lymphocytes is thought to be an important trigger that accelerates the immune response and is followed by hypercytokinemia.

Therefore, using cyclosporine to suppress the activity of T lymphocytes is a reasonable treatment for SS accompanied with TAFRO syndrome-like pathophysiology.

It might also be useful to administer tolvaptan or eltrombopag before the effects of immunosuppressants appear.

If refractory inflammation with anasarca, thrombocytopenia, or lymphadenopathy is observed in an SS patient, complications with TAFRO syndrome-like pathophysiology should be considered.

American Psychological Association (APA)

Suzuki, Eiji& Ichimura, Takuya& Kimura, Satoru& Kanno, Takashi& Migita, Kiyoshi. 2020. Primary Sjögren’s Syndrome Accompanied by Clinical Features of TAFRO Syndrome. Case Reports in Rheumatology،Vol. 2020, no. 2020, pp.1-7.
https://search.emarefa.net/detail/BIM-1151235

Modern Language Association (MLA)

Suzuki, Eiji…[et al.]. Primary Sjögren’s Syndrome Accompanied by Clinical Features of TAFRO Syndrome. Case Reports in Rheumatology No. 2020 (2020), pp.1-7.
https://search.emarefa.net/detail/BIM-1151235

American Medical Association (AMA)

Suzuki, Eiji& Ichimura, Takuya& Kimura, Satoru& Kanno, Takashi& Migita, Kiyoshi. Primary Sjögren’s Syndrome Accompanied by Clinical Features of TAFRO Syndrome. Case Reports in Rheumatology. 2020. Vol. 2020, no. 2020, pp.1-7.
https://search.emarefa.net/detail/BIM-1151235

Data Type

Journal Articles

Language

English

Notes

Includes bibliographical references

Record ID

BIM-1151235